Jim Simons's position in Halozyme Therapeutics is currently worth $1.72 Million. That's 0.00% of their equity portfolio (1925th largest holding). The first Halozyme Therapeutics trade was made in Q4 2013. Since then Jim Simons bought shares eighteen more times and sold shares on 24 occasions. The stake costed the investor $1.05 Million, netting the investor a gain of 64% so far.